San Diego Life Sciences Roundup: Regulus IPO, Fate Funding, & More

Xconomy San Diego — 

The week’s big news in San Diego’s life sciences sector came with the IPO filing by Regulus Therapeutics. The proposed IPO also will test relaxed rules for emerging companies under the new Jump Start Our Business Startups (JOBS) Act. It will be a story worth following, and you can get started here.

—After signing partnerships with AstraZeneca and Biogen-Idec, San Diego’s Regulus Therapeutics filed for an initial public offering that would raise $57.5 million. Regulus, founded five years ago by Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY) and Carlsbad, CA-based Isis Pharmaceuticals (NASDAQ: ISIS) would use the proceeds to fund work on its pipeline of microRNA drugs in pre-clinical development for cancer, hepatitis C, cardiovascular disease, and fibrotic disorders.

Fate Therapeutics, the San Diego startup developing new drugs from stem cell technology, has raised more than $9.2 million from investors, according to a recent regulatory filing. When Venrock partner (and former Idec Pharmaceuticals CEO) Bill Rastetter was named as CEO nine months ago, we reported that Fate had raised more than $50 million in venture capital from Arch Venture Partners, Polaris Venture Partners, OVP Venture Partners, Venrock, and others. VentureWire reports that … Next Page »

Single PageCurrently on Page: 1 2